IKT
Inhibikase Therapeutics, Inc.
Price Chart
Latest Quote
$2.11
+0.10 (+4.98%)
Current Price
| Previous Close | $2.01 |
| Open | $1.96 |
| Day High | $2.15 |
| Day Low | $1.95 |
| Volume | 1,735,617 |
Stock Information
| Shares Outstanding | 157.03M |
| Cash Equivalents | $170.37M |
| Net Income | $-50.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $331.34M |
| EPS (TTM) | $-0.46 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $189.22M |
| Income | $-50.96M |
| Book/sh | $0.98 |
| Cash/sh | $1.08 |
| Employees | 35 |
Financial Ratios
| Quick Ratio | 29.83 |
| Current Ratio | 30.14 |
Returns & Margins
| ROA | -22.61% |
| ROE | -40.23% |
Ownership
| Insider Ownership | 5.40% |
| Institutional Ownership | 78.58% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.55 |
| P/B | 2.14 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $1.97 |
| SMA50 | $1.84 |
| SMA200 | $1.74 |
| RSI | 63.89 |
| ATR | 0.1509 |
| Shares Float | 86.88M |
| Short Float | 23.66% |
| Short Ratio | 23.29 |
| Volatility | 0.94 |
| Rel Volume | 1.49 |
Performance History
| Week | +3.43% |
| Month | +26.35% |
| Quarter | +24.12% |
| 6 Months | +24.12% |
| YTD | +8.21% |
| Year | +13.44% |
| 3 Years | -27.86% |
| 5 Years | -87.07% |
| 10 Years | -96.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.11 | 1,735,600 |
| 2026-07-16 | $2.01 | 584,100 |
| 2026-07-15 | $2.06 | 981,700 |
| 2026-07-14 | $2.06 | 4,077,400 |
| 2026-07-13 | $1.96 | 356,400 |
| 2026-07-10 | $2.04 | 584,700 |
| 2026-07-09 | $2.04 | 621,000 |
| 2026-07-08 | $2.07 | 1,079,500 |
| 2026-07-07 | $2.05 | 1,265,300 |
| 2026-07-06 | $1.98 | 413,700 |
| 2026-07-02 | $1.99 | 678,500 |
| 2026-07-01 | $1.94 | 918,900 |
| 2026-06-30 | $2.03 | 1,523,700 |
| 2026-06-29 | $1.93 | 514,100 |
| 2026-06-26 | $1.91 | 3,820,300 |
| 2026-06-25 | $1.87 | 571,300 |
| 2026-06-24 | $1.87 | 937,800 |
| 2026-06-23 | $1.87 | 546,300 |
| 2026-06-22 | $1.84 | 602,400 |
| 2026-06-18 | $1.83 | 1,484,400 |
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
đ° Latest News
Bank of America Predicts Up to 240% Jump for These 2 âStrong Buyâ Stocks
TipRanks âĸ 2026-02-22T11:15:00Z
Sands Capital Opens $10 Million ServiceTitan Position
Motley Fool âĸ 2026-02-18T17:51:44Z
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company
Simply Wall St. âĸ 2025-12-08T11:27:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $53,348,225 | $28,589,068 | $20,089,792 | $18,128,608 |
| Other Income Expense | $1,373,942 | - | - | - |
| Net Non Operating Interest Income Expense | $3,715,094 | $1,069,182 | $1,060,909 | $74,453 |
| Operating Expense | $53,348,225 | $28,589,068 | $20,089,792 | $18,128,608 |
| Other Operating Expenses | - | - | $-260,501 | $-123,440 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Net Interest Income | $3,715,094 | $1,069,182 | $1,060,909 | $74,453 |
| Interest Income | $3,715,094 | $1,069,182 | $1,060,909 | $74,453 |
| Normalized Income | $-49,633,131 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Net Income From Continuing And Discontinued Operation | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Total Operating Income As Reported | $-51,974,283 | $-28,589,068 | $-20,089,792 | $-18,128,608 |
| Net Income Common Stockholders | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Net Income | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Net Income Including Noncontrolling Interests | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Net Income Continuous Operations | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Pretax Income | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Special Income Charges | $1,373,942 | $0 | - | - |
| Interest Income Non Operating | $3,715,094 | $1,069,182 | $1,060,909 | $74,453 |
| Operating Income | $-53,348,225 | $-28,589,068 | $-20,089,792 | $-18,128,608 |
| Per Share | ||||
| Diluted EPS | $-0.49 | $-1.16 | $-3.16 | $-4.28 |
| Basic EPS | $-0.49 | $-1.16 | $-3.16 | $-4.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,661,668 | $-28,562,796 | $-19,912,394 | $-18,121,885 |
| Total Unusual Items | $1,373,942 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $1,373,942 | $0 | - | - |
| Reconciled Depreciation | $60,499 | $26,272 | $177,398 | $6,723 |
| EBITDA (Bullshit earnings) | $-53,287,726 | $-28,562,796 | $-19,912,394 | $-18,121,885 |
| EBIT | $-53,348,225 | $-28,589,068 | $-20,089,792 | $-18,128,608 |
| Diluted Average Shares | $98,310,190 | $23,712,220 | $6,028,210 | $4,223,099 |
| Basic Average Shares | $98,310,190 | $23,712,220 | $6,028,210 | $4,223,099 |
| Diluted NI Availto Com Stockholders | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Restructuring And Mergern Acquisition | $-1,373,942 | $0 | - | - |
| Research And Development | $29,793,146 | $17,210,548 | $13,618,348 | $12,034,985 |
| Selling General And Administration | $23,555,079 | $11,378,520 | $6,731,945 | $6,217,063 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Total Assets | $181,204,516 | $98,599,846 | $14,506,647 | $24,936,297 |
| Total Non Current Assets | $1,095,121 | $148,537 | $295,599 | $565,175 |
| Other Non Current Assets | $95,121 | - | - | - |
| Non Current Prepaid Assets | $1,000,000 | $0 | - | - |
| Current Assets | $180,109,395 | $98,451,309 | $14,211,048 | $24,371,122 |
| Other Current Assets | $343,374 | $826,473 | $739,179 | $163,452 |
| Prepaid Assets | $1,001,993 | $81,308 | $219,817 | $1,117,616 |
| Cash Cash Equivalents And Short Term Investments | $178,764,028 | $97,543,528 | $13,252,052 | $23,050,173 |
| Cash And Cash Equivalents | $139,220,208 | $56,490,579 | $9,165,179 | $7,188,553 |
| Receivables | - | - | $0 | $39,881 |
| Accounts Receivable | - | - | $0 | $39,881 |
| Cash Financial | - | - | - | $7,188,553 |
| Debt | ||||
| Total Debt | $0 | $110,517 | $240,219 | $351,287 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $90,124 | $205,451 |
| Current Debt And Capital Lease Obligation | - | $110,517 | $150,095 | $145,836 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,300,837 | $3,733,566 | $3,528,725 | $3,900,896 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $90,124 | $205,451 |
| Current Liabilities | $8,300,837 | $3,733,566 | $3,438,601 | $3,695,445 |
| Other Current Liabilities | $3,061,501 | - | - | - |
| Payables And Accrued Expenses | $1,976,641 | $2,623,746 | $2,653,055 | $3,089,612 |
| Payables | $1,158,054 | $943,019 | $1,028,551 | $1,151,173 |
| Accounts Payable | $1,158,054 | $943,019 | $646,767 | $1,151,173 |
| Other Payable | - | - | $381,784 | - |
| Interest Payable | - | - | - | $0 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Total Equity Gross Minority Interest | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Stockholders Equity | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Gains Losses Not Affecting Retained Earnings | $21,802 | $-37,248 | $877 | $104,718 |
| Other Equity Adjustments | $21,802 | $-37,248 | $877 | $104,718 |
| Retained Earnings | $-142,679,800 | $-94,420,611 | $-66,900,725 | $-47,871,842 |
| Other | ||||
| Ordinary Shares Number | $131,691,237 | $69,362,439 | $6,186,280 | $4,204,508 |
| Share Issued | $131,691,237 | $69,362,439 | $6,186,280 | $4,204,508 |
| Tangible Book Value | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Invested Capital | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Working Capital | $171,808,558 | $94,717,743 | $10,772,447 | $20,675,677 |
| Capital Lease Obligations | $0 | $110,517 | $240,219 | $351,287 |
| Total Capitalization | $172,903,679 | $94,866,280 | $10,977,922 | $21,035,401 |
| Additional Paid In Capital | $315,429,986 | $189,254,777 | $77,871,584 | $68,798,301 |
| Capital Stock | $131,691 | $69,362 | $6,186 | $4,224 |
| Common Stock | $131,691 | $69,362 | $6,186 | $4,224 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $0 | $110,517 | $150,095 | $145,836 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,262,695 | $999,303 | $635,451 | $459,997 |
| Current Accrued Expenses | $818,587 | $1,680,727 | $1,624,504 | $1,938,439 |
| Net PPE | $0 | $148,537 | $295,599 | $565,175 |
| Accumulated Depreciation | $0 | $-56,725 | $-30,453 | $-6,723 |
| Gross PPE | $0 | $205,262 | $326,052 | $571,898 |
| Machinery Furniture Equipment | $0 | $103,825 | $103,825 | $89,587 |
| Buildings And Improvements | $0 | $101,437 | $222,227 | $328,643 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $39,543,820 | $41,052,949 | $4,086,873 | $15,861,620 |
| Long Term Capital Lease Obligation | - | $0 | $90,124 | $205,451 |
| Other Properties | - | - | $16,895 | $153,668 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-28,238,487 | $-19,148,067 | $-18,099,281 | $-17,594,358 |
| Operating Activities | ||||
| Operating Cash Flow | $-27,786,464 | $-19,148,067 | $-18,085,043 | $-17,351,103 |
| Cash Flow From Continuing Operating Activities | $-27,786,464 | $-19,148,067 | $-18,085,043 | $-17,351,103 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-452,023 | - | $-14,238 | $-243,255 |
| Investing Cash Flow | $2,053,130 | $-37,004,201 | $11,656,666 | $-16,005,708 |
| Cash Flow From Continuing Investing Activities | $2,053,130 | $-37,004,201 | $11,656,666 | $-16,005,708 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $107,617,495 | $103,477,668 | $8,543,559 | $0 |
| Financing Cash Flow | $108,462,963 | $103,477,668 | $8,405,003 | $-204,769 |
| Cash Flow From Continuing Financing Activities | $108,462,963 | $103,477,668 | $8,405,003 | $-204,769 |
| Net Common Stock Issuance | $107,617,495 | $103,477,668 | $8,543,559 | $0 |
| Common Stock Issuance | $107,617,495 | $103,477,668 | $8,543,559 | $0 |
| Net Other Financing Charges | - | - | $-138,556 | - |
| Other | ||||
| End Cash Position | $139,220,208 | $56,490,579 | $9,165,179 | $7,188,553 |
| Beginning Cash Position | $56,490,579 | $9,165,179 | $7,188,553 | $40,750,133 |
| Changes In Cash | $82,729,629 | $47,325,400 | $1,976,626 | $-33,561,580 |
| Proceeds From Stock Option Exercised | $845,468 | $0 | $0 | $44,142 |
| Net Investment Purchase And Sale | $2,505,153 | $-37,004,201 | $11,670,904 | $-15,762,453 |
| Sale Of Investment | $41,600,000 | $23,450,902 | $41,097,005 | $4,963,009 |
| Purchase Of Investment | $-39,094,847 | $-60,455,103 | $-29,426,101 | $-20,725,462 |
| Net Intangibles Purchase And Sale | $-438,624 | $0 | - | - |
| Purchase Of Intangibles | $-438,624 | $0 | - | - |
| Net PPE Purchase And Sale | $-13,399 | $0 | $-14,238 | $-243,255 |
| Purchase Of PPE | $-13,399 | $0 | $-14,238 | $-243,255 |
| Change In Working Capital | $55,925 | $204,930 | $234,758 | $171,182 |
| Change In Other Current Liabilities | $-110,517 | $-129,702 | $-111,068 | $-9,859 |
| Change In Other Current Assets | $6,316 | $120,790 | $106,416 | $38,055 |
| Change In Payables And Accrued Expense | $1,548,079 | $691,857 | $-642,887 | $-255,929 |
| Change In Accrued Expense | $1,401,252 | $420,075 | $-138,481 | $-317,324 |
| Change In Payable | $146,827 | $271,782 | $-504,406 | $61,395 |
| Change In Account Payable | $146,827 | $271,782 | $-504,406 | $61,395 |
| Change In Prepaid Assets | $-1,387,953 | $-478,015 | $842,416 | $328,657 |
| Other Non Cash Items | $-1,373,942 | - | $31,536 | $67,000 |
| Stock Based Compensation | $15,309,924 | $8,140,617 | $500,148 | $458,147 |
| Asset Impairment Charge | $7,357,294 | $0 | - | - |
| Amortization Of Securities | $-936,975 | $0 | - | - |
| Depreciation Amortization Depletion | $60,499 | $26,272 | $177,398 | $6,723 |
| Depreciation And Amortization | $60,499 | $26,272 | $177,398 | $6,723 |
| Depreciation | $60,499 | $26,272 | $177,398 | $6,723 |
| Net Income From Continuing Operations | $-48,259,189 | $-27,519,886 | $-19,028,883 | $-18,054,155 |
| Change In Receivables | - | $0 | $39,881 | $70,258 |
| Changes In Account Receivables | - | $0 | $39,881 | $70,258 |
| Repayment Of Debt | - | - | $0 | $-248,911 |
| Interest Paid Supplemental Data | - | - | $0 | $973 |
| Net Issuance Payments Of Debt | - | - | $0 | $-248,911 |
| Net Short Term Debt Issuance | - | - | $0 | $-248,911 |
| Short Term Debt Payments | - | - | $0 | $-248,911 |
| Change In Other Working Capital | - | - | - | $38,055 |
| Issuance Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-07-15